Close



Nov 19, 2018 06:02AM
Oct 31, 2018 06:22AM
Oct 31, 2018 06:04AM
Aug 8, 2018 06:19AM
Aug 8, 2018 06:02AM
May 29, 2018 06:02AM
May 8, 2018 06:02AM Egalet Reports First Quarter 2018 Financial Results
May 7, 2018 06:09AM
May 7, 2018 06:02AM
Apr 30, 2018 06:22AM
Apr 30, 2018 06:02AM
Apr 17, 2018 04:02PM
Mar 12, 2018 06:02AM
Feb 20, 2018 06:55AM Egalet (EGLT) Reports Issuance of New U.S. Patent for Guardian Technology
Feb 20, 2018 06:02AM
Jan 24, 2018 06:02AM
Dec 15, 2017 06:03AM
Dec 15, 2017 06:02AM
Nov 8, 2017 06:02AM
Sep 19, 2017 04:00AM
Sep 8, 2017 06:04AM Egalet (EGLT) Announced New Data at PAINWEEK Demonstrating Potential of ARYMO ER to Deter Opioid Abuse
Sep 8, 2017 06:02AM
Aug 14, 2017 10:08AM
Aug 9, 2017 04:02PM
Jul 6, 2017 09:30AM
Jul 5, 2017 05:54PM
Jun 20, 2017 09:10AM
Jun 20, 2017 09:06AM Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO
May 11, 2017 07:20AM
May 10, 2017 06:02AM
Apr 18, 2017 06:24AM
Apr 18, 2017 06:23AM
Mar 30, 2017 06:02AM
Mar 29, 2017 06:09AM
Mar 29, 2017 06:02AM Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™
Jan 18, 2017 04:02PM
Jan 10, 2017 09:23AM
Jan 10, 2017 06:38AM
Jan 9, 2017 06:11PM
Jan 9, 2017 03:32PM
Jan 9, 2017 02:53PM
Jan 9, 2017 02:51PM Egalet Receives FDA Approval for ARYMO™ ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain
Jan 9, 2017 12:15PM

251,872 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All